ArticleJournal of cardiothoracic surgery2025
Elucidating the role of LGALS3BP in coronary atherosclerosis: integrating bioinformatics and machine learning for advanced insights.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Omics Studies in Osteoarthritis: A Review of Molecular Mechanisms and Candidate Molecules.Biomolecules · 2026Review
- Expression, Localization and Actions of Galectin-3: Implications in the Pathophysiology and Therapy of Cardiovascular Disease.International journal of molecular sciences · 2026Review
- Galectin-3 binding protein is upregulated in heart failure with preserved ejection fraction and associated with endothelial nitric oxide synthase deficiency.GeroScience · 2026Article
- γδ T Cells in Autoinflammatory Diseases.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAtherosclerosis (AS) is increasingly recognized as a chronic inflammatory disease that significantly impacts vascular health and contributes to cardiovascular disorders. LGALS3BP, a well-studied molecule, plays key roles in various physiological and pathological processes.
methodsWe identified LGALS3BP as a central focus through integrative analysis of DEGs across multiple datasets (GSE43292 and GSE9820) from the GEO database, combined with immune-related gene sets from the ImmPort database. Advanced analytical techniques, including Lasso regression and SVM-RFE, were used to refine gene selection. GSEA and GSVA revealed significant enrichment in immune-related pathways. The relationship between LGALS3BP expression and immune processes was explored using CIBERSORT and ESTIMATE algorithms, which indicated a positive association between higher LGALS3BP expression and increased immune cell infiltration.
resultsAmong the 10 DEGs associated with LGALS3BP, 13 hub genes were identified via LASSO and SVM-RFE analyses. Functional assays highlighted LGALS3BP's involvement in viral defense, cytokine production, and immune cascades. Increased expression of LGALS3BP was positively correlated with activated dendritic cells, NK cells, memory CD4 T cells, naïve CD4 T cells, CD8 T cells, follicular helper T cells, gamma delta T cells, and regulatory T cells (Tregs), while negatively associated with resting mast cells, M0 macrophages, and eosinophils.
conclusionsOur research elucidates the complex relationship between LGALS3BP and AS, positioning it as a potential novel biomarker for diagnosis and disease monitoring. These findings lay the groundwork for future studies and suggest that targeting LGALS3BP-related pathways could enhance our understanding of AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.